DCC Mediated Coupling for Halofenate Manufacture
    1.
    发明申请
    DCC Mediated Coupling for Halofenate Manufacture 有权
    DCC介导的联苯胺制造

    公开(公告)号:US20140206892A1

    公开(公告)日:2014-07-24

    申请号:US13745315

    申请日:2013-01-18

    申请人: Metabolex, Inc.

    发明人: Jiangao Song

    IPC分类号: C07C231/02

    摘要: The present application discloses a process for the preparation of a halofenate compound of the formula (III) or a salt thereof: wherein R, X and X′ are as defined herein, the process comprising contacting a compound of formula (Ia) with a compound of formula (Ib) and N,N′-dicyclohexylcarbodiimide under conditions sufficient to form the compound of formula (III).

    摘要翻译: 本申请公开了制备式(III)的卤代盐酸盐化合物或其盐的方法:其中R,X和X'如本文所定义,该方法包括使式(Ia)化合物与化合物 式(Ib)和N,N'-二环己基碳二亚胺在足以形成式(III)化合物的条件下反应。

    Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto
    2.
    发明申请
    Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto 有权
    ( - ) - 卤化物的结晶固体和无定形形式及其相关方法

    公开(公告)号:US20140024852A1

    公开(公告)日:2014-01-23

    申请号:US13938548

    申请日:2013-07-10

    IPC分类号: C07C235/78

    摘要: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

    摘要翻译: 本发明提供( - ) - 卤代苯甲酸酯的结晶固体和无定形形式。 结晶固体形式可以用于各种药物组合物中,并且对于预防和/或治疗与哺乳动物血脂沉积相关的病症,特别是涉及2型糖尿病和高脂血症的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物的2型糖尿病和高脂血症的方法,其包括施用治疗有效量的( - ) - 氟酸盐的结晶固体和无定形形式的步骤。